Dimethyl Fumarate: A Review in Relapsing-Remitting MS

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Dimethyl fumarate (Tecfidera®) is an established treatment for relapsing forms of multiple sclerosis (MS).
• Real-world and clinical trial data support its efficacy and long-term benefit in MS patients.

Purpose of the Study:

• To evaluate the effectiveness and tolerability of dimethyl fumarate in treating relapsing-remitting multiple sclerosis (RRMS).
• To assess long-term benefits and safety profile in diverse patient populations.

Main Methods:

• Analysis of pivotal phase III trials (DEFINE, CONFIRM) and a study in East Asian patients (APEX).
• Evaluation of clinical relapse rates, MRI measures of disease activity, disability progression, and health-related quality of life (HR-QoL).

Main Results:

• Twice-daily dimethyl fumarate significantly reduced clinical relapses and MRI-detected disease activity in RRMS patients.
• Improvements in HR-QoL and reduced disability progression were observed.
• Efficacy was consistent across different populations, including East Asian patients.
• Common adverse events (flushing, GI issues) were mild/moderate and manageable.

Conclusions:

• Dimethyl fumarate is a safe and effective oral treatment option for RRMS.
• Its benefits in reducing disease activity and progression are maintained long-term.
• Convenient oral administration enhances patient adherence and treatment outcomes.